alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2015429EN.01002401.xml

| 21.12.2015 | EN | Official Journal of the European Union | C 429/24 |
| --- | --- | --- | --- |

21.12.2015

EN

Official Journal of the European Union

C 429/24

---

Order of the General Court of 29 October 2015 — Hipp v OHIM — Nestlé Nutrition (Praebiotik)

(Case T-315/14) (1)

1

((Community trade mark - Application for revocation - Withdrawal of the registration - No need to adjudicate))

(2015/C 429/31)

Language of the case: German

Parties

Parties

Applicant: Hipp & Co. (Sachseln, Switzerland) (represented by: M. Kinkeldey, A. Wagner and B. Brandstätter, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: D. Walicka, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM intervening before the General Court: Nestlé Nutrition GmbH (Frankfurt-am-Main, Germany) (represented by: A. Schulz and C. Onken, lawyers)

Other party to the proceedings before the Board of Appeal of OHIM intervening before the General Court:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 26 February 2014 (Cases R 1171/2012-4 and R 1326/2012-4) concerning revocation proceedings between Nestlé Nutrition GmbH and Hipp & Co.

Operative part of the order

Operative part of the order

| 1. | There is no longer any need to adjudicate in the action. |
| --- | --- |

1.

There is no longer any need to adjudicate in the action.

| 2. | Hipp & Co. and Nestlé Nutrition GmbH shall each bear their own costs and half of the costs incurred by the Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM). |
| --- | --- |

2.

Hipp & Co. and Nestlé Nutrition GmbH shall each bear their own costs and half of the costs incurred by the Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM).

---

(1)  OJ C 212, 7.7.2014.

1

---
<PAGE>
                                                                     EXHIBIT 23b


                        [RYDER SCOTT COMPANY LETTERHEAD]

                      CONSENT OF RYDER SCOTT COMPANY, L.P.


                  As independent oil and gas consultants, Ryder Scott Company,
L.P., hereby consents to references to our firm in the annual report on Form
10-K of Seven Seas Petroleum Inc. to be filed with the Securities and Exchange
Commission on or about March 29, 2002, and also consents to the incorporation by
reference in such annual report of information from our reserve report dated as
of March 4, 2002.

                                            /s/  Ryder Scott Company, L. P.
                                            --------------------------------
                                                 RYDER SCOTT COMPANY, L.P.


Houston, Texas
March 28, 2002
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7589 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7589

   To direct the Secretary of Commerce, acting through the Assistant 
Secretary of Commerce for Communications and Information, to conduct a 
study of the national security risks posed by consumer routers, modems, 
  and devices that combine a modem and router, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 8, 2024

Mr. Latta (for himself and Mrs. Peltola) introduced the following bill; 
       which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
   To direct the Secretary of Commerce, acting through the Assistant 
Secretary of Commerce for Communications and Information, to conduct a 
study of the national security risks posed by consumer routers, modems, 
  and devices that combine a modem and router, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Removing Our Unsecure Technologies 
to Ensure Reliability and Security Act'' or the ``ROUTERS Act''.

SEC. 2. STUDY OF NATIONAL SECURITY RISKS POSED BY CERTAIN ROUTERS AND 
              MODEMS.

    (a) In General.--The Secretary shall conduct a study of the 
national security risks posed by consumer routers, modems, and devices 
that combine a modem and router that are designed, developed, 
manufactured, or supplied by persons owned by, controlled by, or 
subject to the influence of a covered country.
    (b) Report to Congress.--Not later than 1 year after the date of 
the enactment of this Act, the Secretary shall submit to the Committee 
on Energy and Commerce of the House of Representatives and the 
Committee on Commerce, Science, and Transportation of the Senate a 
report on the results of the study conducted under subsection (a).
    (c) Definitions.--In this section:
            (1) Covered country.--The term ``covered country'' means a 
        country specified in section 4872(d)(2) of title 10, United 
        States Code.
            (2) Secretary.--The term ``Secretary'' means the Secretary 
        of Commerce, acting through the Assistant Secretary of Commerce 
        for Communications and Information.
                                 <all>
```
§ 876.3750 Testicular prosthesis. ( a ) *Identification.* A testicular prosthesis is an implanted device that consists of a solid or gel-filled silicone rubber prosthesis that is implanted surgically to resemble a testicle.
( b ) *Classification.* Class III (premarket approval).
( c ) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before July 5, 1995, for any testicular prosthesis that was in commercial distribution before May 28, 1976, or that has on or before July 5, 1995, been found to be substantially equivalent to a testicular prosthesis that was in commercial distribution before May 28, 1976. Any other testicular prosthesis shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[48 FR 53023, Nov. 23, 1983, as amended at 52 FR 17738, May 11, 1987; 60 FR 17216, Apr. 5, 1995]
Exhibit 99.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

I, Gregory A. Wells, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

To the best of my knowledge and belief, the quarterly report on Form 10-Q filed with the
Securities and Exchange Commission on May 15, 2003, by NTS-Properties VII, Ltd. and to which
this certification is appended (the "Periodic Report") fully complies with the requirements of Section
13(a) of the Securities Exchange Act of 1934, and the information contained in the Periodic Report
fairly presents, in all material respects, the financial condition and results of operations of NTS-
Properties VII, Ltd.

A signed original of this written statement required by Section 906 has been provided to
NTS-Properties VII, Ltd. and will be retained by NTS-Properties VII, Ltd. and furnished to the
Securities and Exchange Commission or its staff upon request.

/s/ Gregory A. Wells
Chief Financial Officer of NTS Capital Corporation,
General Partner of NTS-Properties Associates VII,
General Partner of NTS-Properties VII, Ltd.
EX-421



		

			 

		




		
			EXHIBIT 4.21
		

		
			May 5, 2017
		

		
			﻿
		

		
			Perceptron, Inc.
		

		
			47827 Halyard Dr.
		

		
			Plymouth, Michigan 48170
		

		
			Re:Amended and Restated Credit Agreement dated as of November 16, 2010, by and between Perceptron, Inc. (“Company”) and Comerica Bank (as amended, “Credit Agreement”)
		

		
			Gentlemen:
		

		
			Company has advised Comerica Bank (“Bank”) that it has violated the provisions of Section 7.11 of the Credit Agreement for the period ended March 31, 2017 (the “Covenant Violation”). Company has requested that the Bank waive any Event of Default under the Credit Agreement resulting from the Covenant Violation. The Bank hereby waives the Covenant Violation (“Waiver”).
		

		
			This Waiver shall not be deemed to amend or alter in any respect the terms and conditions of the Credit Agreement, or to constitute a waiver or release by the Bank of any right, remedy Default or Event of Default under the Credit Agreement, except to the extent expressly set forth above. Furthermore, this Waiver shall not affect in any manner whatsoever any rights or remedies of the Bank with respect to any other non-compliance by the Company with the Credit Agreement or the Loan Documents whether in the nature of an Event of Default or otherwise, and whether now in existence or subsequently arising.
		

		
			Except as specifically defined to the contrary herein, capitalized terms used in this Waiver shall have the meanings given them in the Credit Agreement.
		

		
			﻿
		

		
			Very truly yours,
		

		
			﻿
		

		
			COMERICA BANK
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			By: /s/ Lydia R. Mansoor
		

		
			
		

		
			﻿
		

		
			Its: Officer
		

		
			﻿
§ 524.2620 Liquid crystalline trypsin, Peru balsam, castor oil. ( a ) *Specifications.* ( 1 ) Each gram of liquid or aerosol contains 0.12 milligram of crystalline trypsin, 87.0 milligrams of Peru balsam, and 788.0 milligrams of castor oil.
( 2 ) Each gram of liquid or aerosol contains 0.1 milligram of crystalline trypsin, 72.5 milligrams of Peru balsam, and 800 milligrams of castor oil.
( b ) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter for use as in paragraph (c) in this section: ( 1 ) No. 069043 for use of product described in paragraph (a)(1).
( 2 ) No. 017135 for use of product described in paragraph (a)(2).
( c ) *Conditions of use* — ( 1 ) *Amount.* Apply directly to the wound site.
( 2 ) *Indications for use.* As an aid in the treatment of external wounds and assists healing by facilitating the removal of necrotic tissue, exudate, and organic debris.
[79 FR 10973, Feb. 27, 2014, as amended at 88 FR 14901, Mar. 10, 2023]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3340 *Klebsiella* spp. serological reagents. ( a ) *Identification. Klebsiella* spp. serological reagents are devices that consist of antigens and antisera, including antisera conjugated with a fluorescent dye (immunofluorescent reagents), that are used in serological tests to identify *Klebsiella* spp. from cultured isolates derived from clinical specimens. The identification aids in the diagnosis of diseases caused by bacteria belonging to the genus *Klebsiella* and provides epidemiological information on these diseases. These organisms can cause serious urinary tract and pulmonary infections, particularly in hospitalized patients.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 54 FR 25047, June 12, 1989; 66 FR 38792, July 25, 2001]
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.6070 Ultraviolet activator for polymerization. ( a ) *Identification.* An ultraviolet activator for polymerization is a device that produces ultraviolet radiation intended to polymerize (set) resinous dental pit and fissure sealants or restorative materials by transmission of light through a rod.
( b ) *Classification.* Class II.
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Monetary Policy: 1955-56

              																	United States. Congress. Joint Economic Committee. Subcommittee on Economic Stabilization					 and 	Eighty-Fourth Congress, 1955-1957. 						*Monetary Policy: 1955-56 : Hearings Before the Subcommittee on Economic Stabilization of the Joint Economic Committee, Congress of the United States, Eighty-Fourth Congress, Second Session, Pursuant to Sec. 5 (A) of Public Law 304, 79th Congress, December 10 and 11, 1956*,												Washington: 								Government Printing Office, 										December 10 and 11, 1956,									https://fraser.stlouisfed.org/title/388,			accessed on September 22, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.2060 Jaw tracking device. ( a ) *Jaw tracking device for monitoring mandibular jaw positions relative to the maxilla* — ( 1 ) *Identification.* A jaw tracking device for monitoring mandibular jaw positions relative to the maxilla is a nonpowered or electrically powered device that measures and records anatomical distances and angles in three dimensional space, to determine the relative position of the mandible with respect to the location and position of the maxilla, while at rest and during jaw movement.
( 2 ) *Classification.* Class I (general controls). The device is exempt from the premarket notification provisions of subpart E of part 807 of this chapter subject to § 872.9.
( b ) *Jaw tracking device for interpretation of mandibular jaw positions for the diagnosis* — ( 1 ) *Identification.* A jaw tracking device for interpretation of mandibular jaw positions relative to the maxilla for the diagnosis of temporomandibular joint disorders and associated orofacial pain is a nonpowered or electrically powered device that measures and records anatomical distances and angles to determine the relative position of the mandible in three dimensional space, with respect to the location and position of the maxilla, while at rest and during jaw movement. The device records, displays, and stores information about jaw position. The device interprets jaw position to generate meaningful output, either directly or by connection to a personal computer. The device may be a part of a system of devices, contributing jaw position information to be considered with data from other diagnostic components.
( 2 ) *Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Dental Sonography and Jaw Tracking Devices.”
[68 FR 67367, Dec. 2, 2003]
# C_2017030EN.01004301.xml

| 30.1.2017 | EN | Official Journal of the European Union | C 30/43 |
| --- | --- | --- | --- |

30.1.2017

EN

Official Journal of the European Union

C 30/43

---

Judgment of the General Court of 13 December 2016 — European Dynamics Luxembourg and Evropaïki Dynamiki v Commission

(Case T-764/14) (1)

1

((Public service contracts - Call for tender procedure - Technical assistance, development and implementation of a computerised system for the ASEAN customs transit system (ACTS) - Rejection of a tenderer’s bid - Award of the contract to another tenderer - Selection criteria - Award criteria - Obligation to state reasons - Manifest error of assessment - Equal treatment - Openness))

(2017/C 030/46)

Language of the case: Greek

Parties

Parties

Applicants: European Dynamics Luxembourg SA (Luxembourg, Luxembourg) and Evropaïki Dynamiki — Proigmena Sistimata Tilepikoinonion Pliroforikis kai Tilematikis AE (Athens, Greece) (represented initially by: M. Sfyri and I. Ampazis, lawyers, and subsequently by: M. Sfyri)

Applicants:

Defendant: European Commission (represented initially by: S. Bartelt and A. Marcoulli, and subsequently by: S. Bartelt and M. Konstantinidis, acting as Agents)

Defendant:

Re:

Re:

Application on the basis of Article 263 TFEU seeking the annulment of the decision of the Commission of 5 September 2014 rejecting the bid submitted by the applicants in restricted call for tenders procedure EuropeAid/135040/C/SER/MULTI concerning the development of a computerised management system for the ASEAN customs transit system and awarding that contract to another tenderer.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders European Dynamics Luxembourg SA and Evropaïki Dynamiki — Proigmena Sistimata Tilepikoinonion Pliroforikis kai Tilematikis AE to pay the costs. |
| --- | --- |

2.

Orders European Dynamics Luxembourg SA and Evropaïki Dynamiki — Proigmena Sistimata Tilepikoinonion Pliroforikis kai Tilematikis AE to pay the costs.

---

(1)  OJ C 26, 26.1.2015.

1

---
### C OURT OF 

### A PPEALS FOR THE



### F IRST 

### D ISTRICT OF 

### T EXAS AT 

### H OUSTON



### O RDER ON 

### M OTION

Cause Number: 01

- 11

- 00333

- CV

Trial Court Cause

Number: 0851588

Style: Andrew Whallon, Dahlia Garcia and Richard Grayshaw

v City of Houston

Date motion filed * : April 24, 2015

Type of motion: Motion for Reconsider ation of Motion for Extension of Time to File Appellant’s Motion

for Rehearing

Party filing motion: Appellant Andrew Whallon

Document to be filed: Motion for Rehearing

Is appeal accelerated? Yes No

If motion to extend time:

Original due date: February 20, 2015

Number of previous extensions granted: 0

Date Requested: March 9, 2015

Ordered that motion is:

Granted

If document is to be filed, document due: May 26, 2015

Absent extraordinary circumstances, the Court will not grant additional motions to extend time

Denied

Dismissed ( e.g. , want of jurisdiction, moot)

Other:

Judge's signa ture: /s/ Sherry Radack

Acting individually Acting for the Court

Date: May 5, 2015
§ 74.1708 D&C Yellow No. 8. ( a ) *Identity.* ( 1 ) The color additive D&C Yellow No. 8 is principally the disodium salt of fluorescein.
( 2 ) Color additive mixtures for use in externally applied drugs made with D&C Yellow No. 8 may contain only those diluents that are suitable and that are listed in part 73 of this chapter for use in color additive mixtures for coloring externally applied drugs.
( b ) *Specifications.* D&C Yellow No. 8 shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Sum of water and chlorides and sulfates (calculated as sodium salts), not more than 15 percent. Matter insoluble in alkaline water, not more than 0.3 percent. Resorcinol, not more than 0.5 percent. Phthalic acid, not more than 1 percent. 2-(2,4-Dihydroxybenzoyl) benzoic acid, not more than 0.5 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 85 percent.
( c ) *Uses and restrictions.* D&C Yellow No. 8 may be safely used in externally applied drugs in amounts consistent with good manufacturing practice.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Yellow No. 8 shall be certified in accordance with regulations in part 80 of this chapter.
**Exhibit 32.1****CERTIFICATION**Each of the undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted pursuant toSection 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Vitran CorporationInc., that, to his knowledge, the Annual Report of Vitran Corporation Inc. on Form 10-K/A for theyear ended December 31, 2007, fully complies with the requirements of Section 13(a) of theSecurities Exchange Act of 1934 and that the information contained in such report fairly presents,in all material respects, the financial condition and results of operation of Vitran CorporationInc.        Date:     February 15, 2008                     By:  /s/  RICHARD E. GAETZ    Richard E. Gaetz    President and
<PAGE>   1
                                                                    Exhibit 23.2


               Consent of Ernst & Young LLP, Independent Auditors

We consent to the incorporation by reference in the Registration Statement (Form
S-8) pertaining to the Illuminet Holdings, Inc. 1997 Equity Incentive Plan and
Illuminet Holdings, Inc. 1999 Stock Purchase Plan, of our report dated February
12, 1999, except Note 12, as to which the date is October 7, 1999 with respect
to the consolidated financial statements of Illuminet Holdings, Inc. included in
the final Prospectus filed with the Securities and Exchange Commission dated
October 7, 1999.

Seattle, Washington                                        /s/ Ernst & Young LLP
October 12, 1999                                           ---------------------
                                                           ERNST & YOUNG LLP
Court of Appeals

Sixth Appellate District of Texas

J U D G M E N T

Robert G. Walker, Appellant

No. 06-23-00075-CV v.

Lamar County, et al., Appellees

Appeal from the 62nd District Court of 

Lamar County, Texas (Tr. Ct. No. 89503). 

Memorandum Opinion delivered by Justice 

van Cleef, Chief Justice Stevens and Justice 

Rambin participating. 

As stated in the Court’s opinion of this date, we find that the appeal should be dismissed 

for want of prosecution. Therefore, we dismiss the appeal.

We note that the appellant, Robert G. Walker, has adequately indicated his inability to 

pay costs of appeal. Therefore, we waive payment of costs.

RENDERED DECEMBER 8, 2023

BY ORDER OF THE COURT

SCOTT E. STEVENS

CHIEF JUSTICE

ATTEST:

Debra K. Autrey, Clerk
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1930 Stethoscope head. ( a ) *Identification.* A stethoscope head is a weighted chest piece used during anesthesia to listen to a patient's heart, breath, and other physiological sounds.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 54 FR 25048, June 12, 1989; 66 FR 38793, July 25, 2001]
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3100 Dental amalgamator. ( a ) *Identification.* A dental amalgamator is a device, usually AC-powered, intended to mix, by shaking, amalgam capsules containing mercury and dental alloy particles, such as silver, tin, zinc, and copper. The mixed dental amalgam material is intended for filling dental caries.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9.
[55 FR 48439, Nov. 20, 1990, as amended at 59 FR 63008, Dec. 7, 1994; 66 FR 38797, July 25, 2001]